Novel theapeutic approacheClinical experiences with tolterodine
References (0)
Cited by (32)
Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females
2016, Drug Metabolism and PharmacokineticsCitation Excerpt :While tolterodine itself has no detectable effect on CYP2D6, CYP3A4, CYP2C19 and CYP1A2 [7], it is known to be a sensitive substrate of CYP2D6. Tolterodine is eliminated primarily by metabolism involving CYP2D6 and CYP3A4 [8,9] and undergoes metabolism to form the 5-hydroxymethyl tolterodine (5-HMT) derivative [10,11], a major metabolite which is pharmacologically active and has equivalent antimuscarinic potency to tolterodine in vitro [12]. Serum concentrations of tolterodine were higher in CYP2D6 poor metabolizers (PMs) than in extensive metabolizers (EMs), and the AUC of tolterodine was increased by 4.8-fold in CYP2D6 EM with fluoxetine 20 mg, which is known as a potent CYP2D6 inhibitor [13].
Tolterodine
2007, xPharm: The Comprehensive Pharmacology ReferenceHigh performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma
2005, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCharacterization of a new muscarinic receptor antagonist PNU-171990 in guinea pig, cat and human smooth muscle
2002, European Journal of Pharmacology
Copyright © 2001 Published by Elsevier Inc. All rights reserved.